Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.77 |
| ▸ | KDR | P35968 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 5/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | CA7 | P43166 | 4/20 | 0.54 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6586572 | 0.91 | TRPV1 (0.64) | TRPV1KDRCA9CA1CA2 | |
| SCHEMBL6580902 | 0.90 | TRPV1 (0.72) | TRPV1KDRCA9CA1CA2 | |
| SCHEMBL6670457 | 0.90 | TRPV1 (0.72) | TRPV1KDRCA9CA1CA2 | |
| SCHEMBL6584798 | 0.87 | TRPV1 (1.00) | TRPV1KDRCA9CA1CA2 | |
| SCHEMBL6582498 | 0.85 | TRPV1 (0.70) | TRPV1KDRCA9CA1CA2 | |
| SCHEMBL281864 | 0.83 | KDR (0.85) | TRPV1KDRCA9CA1CA2 | |
| SCHEMBL6583331 | 0.82 | TRPV1 (0.61) | TRPV1KDRCA9CA1CA2 | |
| SCHEMBL118026 | 0.82 | KDR (1.00) | TRPV1KDRCA9CA1CA2 | |
| SCHEMBL29364392 | 0.82 | KDR (1.00) | TRPV1KDRCA9CA1CA2 | |
| SCHEMBL26697308 | 0.80 | KDR (0.74) | TRPV1KDRCA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259875-A1 | Amine derivatives | BAYER HEALTHCARE AG (DE) | 2004-12-23 | — | — | US | claimed |
| WO-2004028440-A2 | VR1 ANTAGONISTS FOR THE TREATMENT OF UROLOGICAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2004-04-08 | — | — | WO | claimed |
| US-20040259875-A1 | Amine derivatives | BAYER HEALTHCARE AG (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1414788-A1 | NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | Bayer HealthCare AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2004028440-A2 | VR1 ANTAGONISTS FOR THE TREATMENT OF UROLOGICAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2004-04-08 | — | — | WO | disclosed |
| WO-2003014064-A1 | NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259875-A1 | Amine derivatives | AVPR1A, GRIN1, OPRL1 | TRPV1 14/4885KDR 615/4885CA9 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.